QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
NASDAQ:BCRX

BioCryst Pharmaceuticals - BCRX Price Target & Analyst Ratings

$8.46
-0.04 (-0.47%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$8.37
▼
$8.57
50-Day Range
$7.94
▼
$11.01
52-Week Range
$7.61
▼
$18.00
Volume
1.42 million shs
Average Volume
3.07 million shs
Market Capitalization
$1.59 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.78

BioCryst Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 9 Analyst Ratings

Consensus Analyst Price Target

$15.78
86.50% Upside
High Prediction$30.00
Average Prediction$15.78
Low Prediction$10.00
TypeCurrent
3/27/22 to 3/27/23		1 Month Ago
2/25/22 to 2/25/23		3 Months Ago
12/27/21 to 12/27/22		1 Year Ago
3/27/21 to 3/27/22
Consensus Rating
Moderate Buy
Moderate Buy
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
6 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$15.78$16.11$16.43$21.00
Predicted Upside86.50% Upside57.41% Upside32.11% Upside39.40% Upside
Get BioCryst Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.

BCRX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BCRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BioCryst Pharmaceuticals Stock vs. The Competition

TypeBioCryst PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.56
2.64
2.47
Consensus RatingModerate BuyBuyHold
Predicted Upside86.50% Upside2,002.72% Upside22.47% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/14/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingSector Perform$10.00+20.19%
2/22/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMarket Outperform$16.00+85.19%
2/22/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy$30.00+247.22%
2/22/2023Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy$14.00+62.04%
12/16/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$12.00 ➝ $10.00-7.49%
11/2/2022Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeIn-Line ➝ Outperform$14.00 ➝ $16.00+34.91%
8/5/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform
5/9/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		P. Stavropoulos
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOverweight
5/5/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$24.00 ➝ $19.00+93.88%
4/11/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral$21.00 ➝ $14.00+25.90%
8/6/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold$19.00+8.32%
6/17/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform$18.00 ➝ $21.00+30.60%
3/17/2021JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetPositive ➝ Overweight$10.00 ➝ $15.00+15.30%
6/16/2020BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageNeutral
(Data available from 3/27/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












BCRX Price Target - Frequently Asked Questions

What is BioCryst Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for BioCryst Pharmaceuticals stock is Moderate Buy based on the current 4 hold ratings and 5 buy ratings for BCRX. The average twelve-month price prediction for BioCryst Pharmaceuticals is $15.78 with a high price target of $30.00 and a low price target of $10.00. Learn more on BCRX's analyst rating history.

Do Wall Street analysts like BioCryst Pharmaceuticals more than its competitors?

Analysts like BioCryst Pharmaceuticals less than other Medical companies. The consensus rating for BioCryst Pharmaceuticals is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how BCRX compares to other companies.

Is BioCryst Pharmaceuticals being upgraded by Wall Street analysts?

Over the previous 90 days, BioCryst Pharmaceuticals's stock had 1 upgrade by analysts.

Does BioCryst Pharmaceuticals's stock price have much upside?

According to analysts, BioCryst Pharmaceuticals's stock has a predicted upside of 61.12% based on their 12-month price targets.

What analysts cover BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals has been rated by HC Wainwright, JMP Securities, Needham & Company LLC, and Royal Bank of Canada in the past 90 days.


Stock Ratings Reports and Tools

Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
Ratings for Popular Stocks:
This page (NASDAQ:BCRX) was last updated on 3/27/2023 by MarketBeat.com Staff